Study Links Opioids After Surgery to Brain Cell Damage

For older adults, surgery can be more than a physical challenge — it may also carry lasting consequences for memory and cognitive function. A new preclinical study published in Brain, Behavior, and Immunity (Muscat et al., 2026) sheds light on a previously underexplored mechanism behind this phenomenon, suggesting that opioid use during and after surgery may contribute to persistent cognitive impairment in aged individuals by disrupting the energy-producing machinery inside brain cells. While the research was conducted in rats and human data is still needed, the findings point toward meaningful therapeutic targets that could one day protect aging patients from one of surgery's most underrecognized complications.

What This Study Found

Researchers used an aged rat model to examine what happens in the brain when surgery is combined with perioperative morphine administration — a scenario that closely mirrors common clinical practice. The study's central question was: why do some older patients experience memory problems that persist long after their bodies have healed?

The investigators found that the memory impairments observed in surgery-and-morphine-treated animals were not caused by systemic illness or widespread cell death. Instead, the damage appeared to be highly targeted. Researchers found selective reductions in dendritic spine subtypes — the tiny structural projections on neurons responsible for synaptic stability and communication. The animals also showed impaired late-phase long-term potentiation (LTP), a cellular process considered essential for forming lasting memories, as well as a blunted ability to upregulate GluA1, a key component of AMPA receptors involved in learning.

Alongside these synaptic changes, the study identified elevated levels of neurofilament light chain (Nf-L) in circulation — a biomarker associated with axonal injury. This finding suggests that structural damage to nerve fibers may be ongoing even after the acute surgical period has passed.

Perhaps most significantly, surgery and morphine treatment produced persistent mitochondrial dysfunction specifically within hippocampal tissue — the brain region most closely associated with memory formation. This dysfunction was characterized by impaired oxidative phosphorylation, reduced respiratory reserve capacity, and increased DNA oxidation. Critically, the same mitochondrial deficits were not observed in liver tissue, suggesting the effect is not a body-wide metabolic problem but rather a brain-specific vulnerability.

To probe the mechanistic chain of events, researchers pharmacologically inhibited TLR4 signaling — a key pathway in central neuroinflammation — at the time of surgery. This intervention, which had previously been shown to rescue memory deficits in similar models, was found to reduce oxidative stress and partially restore mitochondrial function. The study suggests that early neuroinflammatory signaling may help set the stage for long-term mitochondrial impairment.

In a particularly compelling finding, researchers administered SS-31 — a mitochondria-targeted peptide — four weeks after surgery, when cognitive deficits were already established. Despite persistent DNA oxidation and continued elevation of Nf-L, SS-31 treatment robustly rescued hippocampal-dependent memory and normalized mitochondrial respiratory function. The study suggests that even after injury has taken hold, targeting mitochondrial bioenergetics may offer a meaningful path to cognitive recovery.

Clinical Significance

Postoperative cognitive dysfunction (POCD) affects a substantial proportion of older surgical patients and can persist for months or even years. Despite its prevalence, POCD remains poorly understood in terms of underlying mechanisms, and there are currently no approved pharmacological treatments specifically targeting it.

This research is significant because it proposes a specific, testable mechanistic pathway: opioid exposure in the perioperative setting triggers neuroinflammation, which in turn causes lasting mitochondrial dysfunction in the hippocampus, ultimately impairing memory. By identifying this chain of events in an aged animal model, the study provides a framework that researchers can now work to validate in human populations.

The role of mitochondria in cognitive aging is an area of growing scientific interest. Neurons are among the most energy-demanding cells in the body, and the hippocampus in particular is highly sensitive to disruptions in mitochondrial function. The study suggests that the aging brain may be especially vulnerable to mitochondrial stress triggered by the combined insult of surgery and opioid exposure — a finding with direct relevance for the millions of older adults who undergo surgery each year.

The effectiveness of SS-31 in the post-injury window is also clinically noteworthy. The study suggests that a therapeutic window may exist even after cognitive symptoms have emerged, raising the possibility of interventions that could help patients who are already experiencing POCD rather than solely focusing on prevention.

It is important to emphasize that this study was conducted in rats, and the findings have not yet been replicated in human clinical trials. Translating these results to human patients will require further investigation, including safety and efficacy studies in human subjects.

Current Access and Compliance Context

SS-31, also known as elamipretide, is a mitochondria-targeting tetrapeptide that has been studied in a range of preclinical models of mitochondrial dysfunction, ischemia-reperfusion injury, and aging-related conditions. It is not currently approved by the U.S. Food and Drug Administration (FDA) for any indication, though it has been investigated in human clinical trials for conditions such as heart failure and Barth syndrome.

In the United States and many other countries, peptides used in research or clinical contexts fall under regulatory frameworks that govern compounding pharmacies, investigational new drug (IND) applications, and off-label prescribing. Patients interested in peptide-based therapies should work exclusively with licensed medical professionals who operate within applicable regulatory guidelines.

Physicians and researchers exploring mitochondrial peptides like SS-31 in the context of cognitive health or perioperative medicine should be aware that the current evidence base is largely preclinical. Responsible clinical use requires informed consent, appropriate patient selection, and adherence to all relevant institutional and regulatory protocols.

What Patients Should Know

If you or a loved one is an older adult facing surgery, the possibility of postoperative cognitive changes is worth discussing with your medical team before the procedure. While POCD is not inevitable, research suggests that certain factors — including the type and duration of opioid use — may influence cognitive outcomes in aging individuals.

Key takeaways from this research for patients include:

• Memory changes after surgery in older adults may have a biological basis rooted in brain cell energy disruption, not simply stress or anesthesia.
• Opioid use in the perioperative setting may be a contributing factor to long-term cognitive impairment, according to this animal study — though more human research is needed to confirm this relationship.
• Mitochondrial health is an emerging area of interest in cognitive aging, and supporting cellular energy function may eventually prove relevant to protecting brain health around the time of surgery.
• No peptide or supplement should be used without guidance from a qualified healthcare provider. The findings discussed here are based on animal research and do not constitute a treatment recommendation.

Speak openly with your surgeon, anesthesiologist, and primary care physician about your concerns regarding cognitive health. Ask about multimodal pain management strategies that may reduce reliance on opioids where clinically appropriate, and discuss any existing risk factors for cognitive decline.

Conclusion

The research by Muscat and colleagues represents an important step toward understanding why surgery can leave lasting marks on memory in older patients. By identifying sustained hippocampal mitochondrial dysfunction as a central mechanism — and demonstrating that a mitochondria-targeted peptide can rescue memory function even after injury is established — the study opens new avenues for both prevention and treatment of POCD. While human clinical evidence is still needed, these findings underscore the growing importance of mitochondrial bioenergetics in the future of cognitive health medicine.

If you are interested in learning more about evidence-based peptide therapies and connecting with a qualified physician who stays current with emerging research, visit peptideassociation.org/find-a-doctor to find a knowledgeable provider in your area.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The research discussed was conducted in an aged rat model; findings have not been confirmed in human clinical trials. Always consult a licensed and qualified healthcare professional before making any decisions about your health, medications, or therapies. The Peptide Association does not endorse any specific treatment protocol.

---

Citation: Muscat SM, Deems NP, Alvarez BD, et al. Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats. Brain Behav Immun. 2026;(published online ahead of print). doi:10.1016/j.bbi.2026.106942. PMID: 42546889.